Treatment for prostate cancer with limited metastasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3 trial evaluates the effectiveness of metastasis-directed therapy in patients with castration-refractory prostate cancer who have up to five progressive lesions. It is a multicentric, randomized, open-label trial that aims to assess the impact of progression-directed therapy on overall survival. Participants will be randomly assigned to receive either radiotherapy or metastasectomy, with stratification based on the number of metastases and type of systemic therapy. The study seeks to determine the best approach to manage oligoprogressive disease in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants eligible for inclusion in this Trial must meet all the following criteria:

* Written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
* Acinar adenocarcinoma (inclusive neuro-endocrine dedifferentiation).
* Oligoprogressive disease on conventional imagine within a maximum of 6 weeks prior to randomisation defined as: a maximum of 3 extracranial progressive lesions (pre-existing lesions, the development of new lesions, or both) in any organ. Nodal (N1) disease should be measured in the short axis. Nodes more than 1.5 cm in the short axis are considered pathologic and measurable. Oligoprogression on bone scan is defined as the occurrence of maximal 3 new and/or progressive lesions. In case of not unambiguously, additional imaging such as diagnostic magnetic resonance imaging (MRI) or dedicated CT-scan should be performed. Visceral disease reported separately (lung, liver, adrenal, or CNS) and is considered measurable if an individual lesions is more than 1 cm longest dimension.

In case of locally persistent/recurrent disease, a diagnostic MRI of the prostate (bed) and/or biopsy of the site is recommended. There are two different mCRPC patient groups who are eligible for inclusion in the trial:

1. Patients with oligoprogressive disease with pADT only as ongoing treatment (Type 1).
2. Patients with oligoprogressive disease with pADT +/- second line systemic therapy. This is both the combination of pADT + ARTA as ongoing treatment or patients who had received docetaxel in the past (Type 2).

   * Castration-refractory disease, defined as testosterone level \< 50 ng/dL.
   * Prior treatment of the primary tumor by radiotherapy or surgery. If the primary tumor has not been treated previously, this treatment is obligatory within the trial.
   * WHO performance 0-2
   * Age \>= 18 years old
   * Absence of psychological, sociological, or geographical condition potentially hampering compliance with study protocol.
   * Patients must be presented at the multidisciplinary board meeting and the inclusion in the trial needs approval by this board.

Exclusion Criteria:

* Ductal adenocarcinoma and small-cell prostate cancer.
* Serum testosterone level \> 50 ng/ml.
* Presence of poly-progressive disease, defined as more than 3 progressive lesions on conventional imaging or nodal and/or metastatic lesions on conventional imaging
* Active malignancy other than prostate cancer that could potentially interfere with the interpretation of this trial.
* Previous treatments (RT, surgery) or comorbidities rendering new treatment with SBRT impossible.
* Spinal bone lesion that is highly symptomatic, neurologically threatening or at risk of fracture.
* Patients already treated with radionuclides, cabazitaxel or PARP-inhibitors in the past.
* Patients with progressive disease while receiving docetaxel.
* Not able to understand the treatment protocol or sign informed consent.

Where it's running

• University Hospitals Leuven
  Leuven, Belgium Recruiting

Study contacts

• Principal investigator: Gert De Meerleer, MD, PhD — Universitaire Ziekenhuizen KU Leuven
• Study coordinator: Kato Rans, MD
• Email: kato.rans@uzleuven.be
• Phone: 003216347600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using targeted radiation therapy for prostate cancer that resists standard treatment

  This study is testing a new type of targeted radiation therapy for men with prostate cancer that isn't responding to standard treatment, to see if it can help control their cancer while they continue their current medication.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT04838899

• MRT-2359 plus apalutamide in advanced prostate cancer

  This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.

  Recruiting at 7 sites Phase 2 Monte Rosa Therapeutics, Inc · Los Angeles, California and 13 other locations · NCT07745361

• JANX014 for metastatic castration-resistant prostate cancer

  This trial will test whether JANX014 is safe, how your body handles it, and whether it shows signs of benefit in adults with metastatic castration-resistant prostate cancer who have already had anti-androgen therapy and typically a taxane.

  Recruiting at 6 sites Phase 1 Janux Therapeutics · La Jolla, California and 5 other locations · NCT07545811

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Terbium‑161 RAD402 treatment for castration‑resistant prostate cancer

  This will test a radioactive antibody called 161Tb‑RAD402 to see if it is safe and can help men with castration‑resistant prostate cancer whose disease has progressed after prior treatments.

  Recruiting at 2 sites Phase 1/2 Radiopharm Theranostics, Ltd · Wollongong, New South Wales and 1 other locations · NCT07259213

• DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers

  This trial will test whether the oral drug DCC-2812 is safe and shows early signs of benefit for people with advanced kidney (renal cell), bladder (urothelial), or castration-resistant prostate cancer.

  Recruiting at 8 sites Phase 1 Deciphera Pharmaceuticals, LLC · Boston, Massachusetts and 7 other locations · NCT06966024

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.